Vertex Pharmaceuticals Incorporated
VRTX
$477.89
$3.620.76%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.97B | 11.69B | 11.39B | 11.09B | 11.02B |
| Total Other Revenue | 30.70M | 30.70M | 30.70M | 10.00M | -- |
| Total Revenue | 12.00B | 11.72B | 11.42B | 11.10B | 11.02B |
| Cost of Revenue | 5.56B | 5.54B | 5.42B | 5.37B | 5.16B |
| Gross Profit | 6.44B | 6.18B | 6.00B | 5.73B | 5.86B |
| SG&A Expenses | 1.75B | 1.64B | 1.57B | 1.52B | 1.46B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.31B | 7.19B | 6.99B | 6.89B | 6.63B |
| Operating Income | 4.69B | 4.54B | 4.43B | 4.21B | 4.40B |
| Income Before Tax | 4.64B | 4.45B | 4.37B | -300.20M | 248.50M |
| Income Tax Expenses | 690.00M | 773.60M | 736.40M | 688.70M | 784.10M |
| Earnings from Continuing Operations | 3.95K | 3.68K | 3.64K | -988.90 | -535.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.95B | 3.68B | 3.64B | -988.90M | -535.60M |
| EBIT | 4.69B | 4.54B | 4.43B | 4.21B | 4.40B |
| EBITDA | 4.87B | 4.71B | 4.60B | 4.39B | 4.58B |
| EPS Basic | 15.47 | 14.32 | 14.14 | -3.81 | -2.07 |
| Normalized Basic EPS | 12.61 | 12.17 | 11.86 | 11.34 | 11.84 |
| EPS Diluted | 15.33 | 14.18 | 13.99 | -3.92 | -2.20 |
| Normalized Diluted EPS | 12.50 | 12.06 | 11.74 | 11.24 | 11.73 |
| Average Basic Shares Outstanding | 1.02B | 1.03B | 1.03B | 1.03B | 1.03B |
| Average Diluted Shares Outstanding | 1.03B | 1.04B | 1.04B | 1.04B | 1.04B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |